{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu J"],"funding":["National Cancer Institute","American Lebanese Syrian Associated Charities","NCI NIH HHS"],"pagination":["1235-1248"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9502026"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(6)"],"pubmed_abstract":["For the cancer clinical trials with immunotherapy and molecularly targeted therapy, time-to-event endpoint is often a desired endpoint. In this paper, we present an event-driven approach for Bayesian one-stage and two-stage single-arm phase II trial designs. Two versions of Bayesian one-stage designs were proposed with executable algorithms and meanwhile, we also develop theoretical relationships between the frequentist and Bayesian designs. These findings help investigators who want to design a trial using Bayesian approach have an explicit understanding of how the frequentist properties can be achieved. Moreover, the proposed Bayesian designs using the exact posterior distributions accommodate the single-arm phase II trials with small sample sizes. We also proposed an optimal two-stage a"],"journal":["Pharmaceutical statistics"],"pubmed_title":["Bayesian single-arm phase II trial designs with time-to-event endpoints."],"pmcid":["PMC9502026"],"funding_grant_id":["P30 CA177558","P30CA177558"],"pubmed_authors":["Pan H","Wu J","Hsu CW"],"additional_accession":[]},"is_claimable":false,"name":"Bayesian single-arm phase II trial designs with time-to-event endpoints.","description":"For the cancer clinical trials with immunotherapy and molecularly targeted therapy, time-to-event endpoint is often a desired endpoint. In this paper, we present an event-driven approach for Bayesian one-stage and two-stage single-arm phase II trial designs. Two versions of Bayesian one-stage designs were proposed with executable algorithms and meanwhile, we also develop theoretical relationships between the frequentist and Bayesian designs. These findings help investigators who want to design a trial using Bayesian approach have an explicit understanding of how the frequentist properties can be achieved. Moreover, the proposed Bayesian designs using the exact posterior distributions accommodate the single-arm phase II trials with small sample sizes. We also proposed an optimal two-stage a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-18T20:52:12.638Z","creation":"2025-04-07T08:56:04.989Z"},"accession":"S-EPMC9502026","cross_references":{"pubmed":["34085764"],"doi":["10.1002/pst.2143"]}}